Irish board wants to keep 2013 drug fees at around current level
This article was originally published in Scrip
The Irish Medicines Board is inviting feedback on its plans to ensure that its fees for various drug and device-related activities in 2013 are kept at more or less the current level. Though the IMB plans to introduce some new fee types, it has proposed some "adjustments" to the fee structure so that there is no overall increase.
You may also be interested in...
The risk of psychiatric disorders with chloroquine and hydroxychloroquine-containing medicines received renewed attention in the EU after they were being used as potential treatments for COVID-19.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.